Madrigal Corp (MDGL) - Long-Term Debt to Capital Coefficient

Madrigal Corp - graphic logo of issuer MDGL

Madrigal Pharmaceuticals (MDGL) delegates production and testing to external contractors to focus on liver therapy. The business is currently scaling sales of the world's first NASH drug in the US. This price trend chart with the 0.66 indicator complements the strategic analysis. The company's success relies on insurance coverage, Rezdiffra prescription rates, and sufficient free cash flow.

Madrigal Pharmaceuticals Inc (MDGL): Long-Term Debt to Equity from 07/04/2022 to 10/31/2026

Comprehensive metric breakdowns and analytics for Madrigal Pharmaceuticals (MDGL)

- stock price and consensus target price:
Quote Chart Madrigal Pharmaceuticals Inc|MDGL - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Madrigal Pharmaceuticals, Inc.|MDGL - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Madrigal Pharmaceuticals|MDGL - Company Book Value|Market Value to Book Value madrigalpharma.com|MDGL - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Madrigal Pharmaceuticals|MDGL - Long-Term Debt to Capital|Short-Term Debt to Capital madrigalpharma.com|MDGL - Company Total Debt|Debt to Net Assets Ratio Madrigal Pharmaceuticals, Inc.|MDGL - Company Long-Term Debt|Company Current Liabilities Madrigal Pharmaceuticals|Immediate Liquidity madrigalpharma.com
- net income and valuation ratios data:
MDGL - Net Income
General company analysis:Madrigal Pharmaceuticals Inc - MDGL
Signature product of Madrigal Pharmaceuticals

For Madrigal Pharmaceuticals (MDGL), which maintains leadership in liver disease therapy, the ratio of long-term debt to equity reflects a financing strategy aimed at expanding into an untapped market. This indicator compares liabilities with maturities exceeding one year against net asset value, measuring the company's reliance on borrowed funds for growth and its resilience to changes in debt service costs amid intensifying competition.

Analysis of competing companies

Ascendis Pharma AS - Long-Term Liabilities to Equity|Long-Term Debt to Capital CORT|RYTM (Rhythm Corp) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital AKRO (Akero Therapeutics)|Long-Term Debt to Capital metsera.com MTSR|MLTX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital 89bio.com|Long-Term Debt to Equity Ratio AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity MiMedx Group MDXG|RZLT - Long-Term Debt to Equity Ratio|Lexicon Pharmaceuticals - Long-Term Debt to Capital|Long-Term Liabilities to Capital mbxbio.com|ALT (Altimmune) - Long-Term Debt to Equity Ratio|AARD: Long-Term Loans to Capital Ratio|SGMT (Sagimet) - Long-Term Debt to Capital|Long-Term Debt to Capital BioAge Labs, Inc|Long-Term Debt to Capital BMEA|Long-Term Debt to Equity QNCX (quincetx.com)|Long-Term Debt to Equity Fractyl Health GUTS|vTv Therapeutics, Inc. (VTVT) - Long-Term Liabilities to Capital|ATPC - Long-Term Debt to Equity|PLUR: Long-Term Debt to Equity|SYBX: Long-Term Debt to Capital|LPCN - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Matinas BioPharma Holdings, Inc.|Spruce Biosciences Inc. (SPRB) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Galecto Corp (GLTO)|Long-Term Debt to Equity Ratio Carmell Therapeutics CTCX|Long-Term Debt to Equity Lumos Pharma, Inc. LUMO|ONVO - Long-Term Debt to Equity Ratio|Radius Recycling - Long-Term Debt to Capital